Developer docs
API playgroundTry for free, no card

Search company profiles

Sustained Therapeutics

Full company profile

uuid000444n

Namestring
Sustained Therapeutics
Legal namestring
Sustained Therapeutics Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release drug delivery platform based on a soft polymer gel that enables localized, long-acting drug release from a single injection. The platform's core technology allows tunable drug release over days, weeks, or months without requiring additional solvents, with a biocompatible formulation designed to minimize systemic side effects. The company was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre and is headquartered at the Jack Bell Research Centre in Vancouver, Canada.

The company is advancing three pipeline candidates: ST-01, a sustained-release lidocaine formulation for chronic scrotal content pain (Phase 2 positive readout in January 2026, with 67% treatment response and 83% clinical response at the 70 mg/mL dose versus control); ST-02, a sustained-release gemcitabine formulation for upper tract urothelial carcinoma delivered via ureteric catheter (Phase II/III underway, targeting orphan indication); and ST-04, a mucoadhesive alprostadil formulation for erectile dysfunction (Phase II planned Q1 2026). The platform's versatility supports potential application across pain, oncology, and sexual health indications.

Sustained Therapeutics is pre-revenue and generates no product sales. The business model is structured around eventual pharmaceutical product commercialization upon regulatory approval, with clinical trials conducted through investigator-sponsored and company-sponsored protocols at multiple Canadian academic medical centers. The company has secured Health Canada regulatory clearances for its trials and is pursuing US regulatory approval for Phase 3 development of ST-01. Its go-to-market strategy targets urologists and pain specialists directly through clinical trial site relationships and conference presentations, including the American Urological Association Annual Meeting.

Short descriptiontext

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release soft polymer gel platform for localized, long-acting drug delivery. It is advancing pipeline candidates ST-01 for chronic pain, ST-02 for urothelial carcinoma, and ST-04 for erectile dysfunction.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sustained-release pharmaceuticals, non-opioid pain therapy, drug delivery platform, clinical-stage biopharmaceutical, localized injectable therapeutics
Industry1 code
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company developing proprietary sustained-release drug products. Revenue expected from product sales upon regulatory approval. Pipeline includes ST-01 for chronic pain, ST-02 for upper tract urothelial carcinoma, and ST-04 for erectile dysfunction.

sec.gov
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ST-01
Description

Sustained-release lidocaine formulation for the treatment of acute and chronic pain

sustainedtherapeutics.com
+2 more records
Core offering1 text field

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a proprietary soft polymer gel drug delivery platform that enables sustained-release, localized injectable therapeutics. The company is advancing a pipeline of candidates targeting non-opioid pain management, urologic oncology, and sexual dysfunction, with three lead programs (ST-01, ST-02, ST-04) currently in or nearing Phase II clinical trials. Products are designed to deliver drug payloads over days, weeks, or months from a single injection at the targeted body site.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 67% treatment response (≥2-point pain reduction) at 70 mg/mL dose vs 26% control (p=0.01)
+3 more records
Product overview1 text field

Sustained Therapeutics is a clinical-stage pharmaceutical company with a patented sustained-release drug delivery platform technology. The company is developing a pipeline of therapeutic candidates including: ST-01 (sustained-release lidocaine for chronic scrotal content pain and postoperative pain), ST-02 (sustained-release gemcitabine for upper tract urothelial carcinoma), and ST-04 (alprostadil for erectile dysfunction). The proprietary platform consists of a soft polymer gel that enables localized, long-lasting drug delivery via injection, designed to release medications over days, weeks, or months depending on formulation.

Product and service3 records
1ST-01
CategorySustained-release pain therapeutics
Description

ST-01 is a sustained-release lidocaine formulation designed for localized, non-opioid treatment of acute and chronic pain. The proprietary soft polymer gel delivers lidocaine slowly over approximately 28 days from a single injection, providing sustained pain relief without opioid dependency risks. It is intended for office-based administration by physicians without specialized training and targets indications including chronic scrotal content pain and postoperative pain.

2ST-02
CategorySustained-release urologic oncology therapeutics
Description

ST-02 is a sustained-release gemcitabine formulation for the treatment of upper tract urothelial carcinoma (UTUC), a urologic oncology indication. It is delivered via ureteric catheter directly to the renal pelvis, where the formulation coats tissue and delivers chemotherapy over an extended period directly at the cancer site. The program may qualify for orphan drug designation, potentially granting seven years of market exclusivity, tax credits, and fee exemptions.

3ST-04
CategorySustained-release sexual medicine therapeutics
Description

ST-04 is a locally delivered erectile dysfunction therapy using a patent-protected mucoadhesive formulation containing alprostadil. It is delivered via transurethral absorption, designed to provide excellent local pharmacokinetics while avoiding systemic delivery, with the intent of fewer side effects compared with current ED therapies.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Vancouver Prostate Centre
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-16
Description

Vancouver Prostate Centre (VPC), a National Centre of Excellence and designated Centre of Excellence for Commercialization and Research, is conducting the investigator-sponsored trial (IST) for ST-02. VPC has received Health Canada approval to conduct the study for ablation of urothelial carcinomas in the upper urinary tract. The partnership leverages VPC's clinical trials facility and world-class translational research program under the same roof.

sustainedtherapeutics.com
2University of British Columbia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sustained Therapeutics was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre. The company was founded by leading urologists and scientists from UBC including Dr. Martin Gleave, Distinguished Professor and Chair of the Department of Urologic Sciences.

sustainedtherapeutics.com
3Dr. Ryan K Flannigan
Strategic tierMinorTypeOthers
Description

Dr. Ryan K Flannigan, Associate Professor at UBC and Director of the Male Reproductive and Sexual Medicine Research Program, served as lead investigator for the Phase 2 study of ST-01 in chronic scrotal content pain, presenting results at AUA 2026.

sustainedtherapeutics.com
4Dr. Peter Black
Strategic tierMinorTypeOthers
Description

Dr. Peter Black, Senior Research Scientist at Vancouver Prostate Centre, is the lead investigator for the Phase II/III clinical trial of ST-02 for Upper Tract Urothelial Carcinoma.

sustainedtherapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Veru is a urology-focused specialty pharma addressing prostate cancer and sexual health. Comparable therapeutic-area focus to Sustained Therapeutics' urology pipeline (ST-01 chronic scrotal pain, ST-02 UTUC, ST-04 erectile dysfunction).

TypeDirect peer
Description

Heron develops sustained-release injectable therapeutics for postoperative pain and oncology supportive care using its proprietary polymer-based delivery platforms. Its Zynrelef (bupivacaine/meloxicam) and oncology-support franchises directly parallel Sustained Therapeutics' ST-01 and ST-02.

TypeBroad incumbent
Description

Endo is a broad specialty pharma with established lidocaine (Lidoderm) and pain franchises. Its former CEO Carol Ammon is a Sustained Therapeutics board member, providing a strategic linkage; comparable in therapeutic area focus if not delivery technology.

TypeDirect peer
Description

DURECT is a specialty pharma company built around sustained-release drug delivery technologies (e.g., POSIMIR, SABER platform) — comparable to Sustained Therapeutics' polymer-gel platform approach. Both companies pursue formulation-based improvements to approved APIs across pain and other indications.

TypeEmerging player
Description

Aquestive is a specialty pharma with proprietary drug delivery platforms (Philmistry, Aqstry) for CNS and allergy therapeutics. Comparable as a platform-based reformulation company seeking to improve approved molecules via novel delivery technologies.

TypeEmerging player
Description

Trevena is a clinical-stage pain pharma focused on novel opioid and non-opioid analgesic mechanisms. While technology differs, it competes in the same chronic/acute pain treatment paradigm Sustained Therapeutics targets with ST-01.

7Innocoll Pharmaceuticals
TypeEmerging player
Description

Innocoll develops biodegradable, sustained-release collagen-based matrices for local drug delivery, including postsurgical pain and surgical site infections. Its local sustained-release approach directly parallels Sustained Therapeutics' ST-01 concept.

TypeEmerging player
Description

Aclaris is a clinical-stage specialty pharma developing novel therapeutics in immunology and oncology. Comparable as a small-cap clinical-stage pharma pursuing reformulation and novel delivery approaches in specialty indications.

TypeDirect peer
Description

Pacira markets Exparel, a sustained-release bupivacaine injectable for postoperative pain — directly comparable to Sustained Therapeutics' ST-01 sustained-release lidocaine strategy. Both target localized, long-acting non-opioid pain control via proprietary injectable depot technology.

TypeBroad incumbent
Description

Collegium is a specialty pain pharmaceutical company focused on abuse-deterrent and non-opioid pain therapies. Its commercial franchise in chronic pain overlaps with Sustained Therapeutics' ST-01 strategic positioning, though Collegium is more commercially mature.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sustained Therapeutics

Specialty Pharmaceuticalssustainedtherapeutics.com

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release soft polymer gel platform for localized, long-acting drug delivery. It is advancing pipeline candidates ST-01 for chronic pain, ST-02 for urothelial carcinoma, and ST-04 for erectile dysfunction.

What Sustained Therapeutics does

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release drug delivery platform based on a soft polymer gel that enables localized, long-acting drug release from a single injection. The platform's core technology allows tunable drug release over days, weeks, or months without requiring additional solvents, with a biocompatible formulation designed to minimize systemic side effects. The company was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre and is headquartered at the Jack Bell Research Centre in Vancouver, Canada.

The company is advancing three pipeline candidates: ST-01, a sustained-release lidocaine formulation for chronic scrotal content pain (Phase 2 positive readout in January 2026, with 67% treatment response and 83% clinical response at the 70 mg/mL dose versus control); ST-02, a sustained-release gemcitabine formulation for upper tract urothelial carcinoma delivered via ureteric catheter (Phase II/III underway, targeting orphan indication); and ST-04, a mucoadhesive alprostadil formulation for erectile dysfunction (Phase II planned Q1 2026). The platform's versatility supports potential application across pain, oncology, and sexual health indications.

Sustained Therapeutics is pre-revenue and generates no product sales. The business model is structured around eventual pharmaceutical product commercialization upon regulatory approval, with clinical trials conducted through investigator-sponsored and company-sponsored protocols at multiple Canadian academic medical centers. The company has secured Health Canada regulatory clearances for its trials and is pursuing US regulatory approval for Phase 3 development of ST-01. Its go-to-market strategy targets urologists and pain specialists directly through clinical trial site relationships and conference presentations, including the American Urological Association Annual Meeting.

Sustained Therapeutics firmographics

Firmographics
Name
Sustained Therapeutics
Legal name
Sustained Therapeutics Inc.
Website
https://sustainedtherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release soft polymer gel platform for localized, long-acting drug delivery. It is advancing pipeline candidates ST-01 for chronic pain, ST-02 for urothelial carcinoma, and ST-04 for erectile dysfunction.
Ownership category
akta.pro rank

Sustained Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Sustained-release pharmaceuticals
  • Non-opioid pain therapy
  • Drug delivery platform
  • Clinical-stage biopharmaceutical
  • Localized injectable therapeutics

Where Sustained Therapeutics is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Sustained Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company developing proprietary sustained-release drug products. Revenue expected from product sales upon regulatory approval. Pipeline includes ST-01 for chronic pain, ST-02 for upper tract urothelial carcinoma, and ST-04 for erectile dysfunction.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Sustained Therapeutics product offering

Product offering

Core offering

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a proprietary soft polymer gel drug delivery platform that enables sustained-release, localized injectable therapeutics. The company is advancing a pipeline of candidates targeting non-opioid pain management, urologic oncology, and sexual dysfunction, with three lead programs (ST-01, ST-02, ST-04) currently in or nearing Phase II clinical trials. Products are designed to deliver drug payloads over days, weeks, or months from a single injection at the targeted body site.

Product overview

Sustained Therapeutics is a clinical-stage pharmaceutical company with a patented sustained-release drug delivery platform technology. The company is developing a pipeline of therapeutic candidates including: ST-01 (sustained-release lidocaine for chronic scrotal content pain and postoperative pain), ST-02 (sustained-release gemcitabine for upper tract urothelial carcinoma), and ST-04 (alprostadil for erectile dysfunction). The proprietary platform consists of a soft polymer gel that enables localized, long-lasting drug delivery via injection, designed to release medications over days, weeks, or months depending on formulation.

Differentiator

Problem solved

Functional benefit

Brands

  • ST-01: Sustained-release lidocaine formulation for the treatment of acute and chronic pain
  • ST-02
  • ST-04

Products and services

  • ST-01 ST-01 is a sustained-release lidocaine formulation designed for localized, non-opioid treatment of acute and chronic pain. The proprietary soft polymer gel delivers lidocaine slowly over approximately 28 days from a single injection, providing sustained pain relief without opioid dependency risks. It is intended for office-based administration by physicians without specialized training and targets indications including chronic scrotal content pain and postoperative pain.
  • ST-02 ST-02 is a sustained-release gemcitabine formulation for the treatment of upper tract urothelial carcinoma (UTUC), a urologic oncology indication. It is delivered via ureteric catheter directly to the renal pelvis, where the formulation coats tissue and delivers chemotherapy over an extended period directly at the cancer site. The program may qualify for orphan drug designation, potentially granting seven years of market exclusivity, tax credits, and fee exemptions.
  • ST-04 ST-04 is a locally delivered erectile dysfunction therapy using a patent-protected mucoadhesive formulation containing alprostadil. It is delivered via transurethral absorption, designed to provide excellent local pharmacokinetics while avoiding systemic delivery, with the intent of fewer side effects compared with current ED therapies.

Quantifiable outcome

  • 67% treatment response (≥2-point pain reduction) at 70 mg/mL dose vs 26% control (p=0.01)
  • +3 more outcomes

Companies that use Sustained Therapeutics

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Sustained Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Sustained Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Vancouver Prostate CentrecoreStrategic or Co-development Partner · 16 November 2023Vancouver Prostate Centre (VPC), a National Centre of Excellence and designated Centre of Excellence for Commercialization and Research, is conducting the investigator-sponsored trial (IST) for ST-02. VPC has received Health Canada approval to conduct the study for ablation of urothelial carcinomas in the upper urinary tract. The partnership leverages VPC's clinical trials facility and world-class translational research program under the same roof.
  • University of British ColumbiacoreStrategic or Co-development PartnerSustained Therapeutics was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre. The company was founded by leading urologists and scientists from UBC including Dr. Martin Gleave, Distinguished Professor and Chair of the Department of Urologic Sciences.
  • Dr. Ryan K FlanniganminorOthersDr. Ryan K Flannigan, Associate Professor at UBC and Director of the Male Reproductive and Sexual Medicine Research Program, served as lead investigator for the Phase 2 study of ST-01 in chronic scrotal content pain, presenting results at AUA 2026.
  • Dr. Peter BlackminorOthersDr. Peter Black, Senior Research Scientist at Vancouver Prostate Centre, is the lead investigator for the Phase II/III clinical trial of ST-02 for Upper Tract Urothelial Carcinoma.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Sustained Therapeutics competitors and assessment

Company assessment

Regional players

  • Veru Inc. Veru is a urology-focused specialty pharma addressing prostate cancer and sexual health. Comparable therapeutic-area focus to Sustained Therapeutics' urology pipeline (ST-01 chronic scrotal pain, ST-02 UTUC, ST-04 erectile dysfunction).

Direct peers

  • Heron Therapeutics: Heron develops sustained-release injectable therapeutics for postoperative pain and oncology supportive care using its proprietary polymer-based delivery platforms. Its Zynrelef (bupivacaine/meloxicam) and oncology-support franchises directly parallel Sustained Therapeutics' ST-01 and ST-02.
  • DURECT Corporation: DURECT is a specialty pharma company built around sustained-release drug delivery technologies (e.g., POSIMIR, SABER platform) — comparable to Sustained Therapeutics' polymer-gel platform approach. Both companies pursue formulation-based improvements to approved APIs across pain and other indications.
  • Pacira BioSciences: Pacira markets Exparel, a sustained-release bupivacaine injectable for postoperative pain — directly comparable to Sustained Therapeutics' ST-01 sustained-release lidocaine strategy. Both target localized, long-acting non-opioid pain control via proprietary injectable depot technology.

Broad incumbents

  • Endo Pharmaceuticals: Endo is a broad specialty pharma with established lidocaine (Lidoderm) and pain franchises. Its former CEO Carol Ammon is a Sustained Therapeutics board member, providing a strategic linkage; comparable in therapeutic area focus if not delivery technology.
  • Collegium Pharmaceutical: Collegium is a specialty pain pharmaceutical company focused on abuse-deterrent and non-opioid pain therapies. Its commercial franchise in chronic pain overlaps with Sustained Therapeutics' ST-01 strategic positioning, though Collegium is more commercially mature.

Emerging players

  • Aquestive Therapeutics: Aquestive is a specialty pharma with proprietary drug delivery platforms (Philmistry, Aqstry) for CNS and allergy therapeutics. Comparable as a platform-based reformulation company seeking to improve approved molecules via novel delivery technologies.
  • Trevena Inc. Trevena is a clinical-stage pain pharma focused on novel opioid and non-opioid analgesic mechanisms. While technology differs, it competes in the same chronic/acute pain treatment paradigm Sustained Therapeutics targets with ST-01.
  • Innocoll Pharmaceuticals: Innocoll develops biodegradable, sustained-release collagen-based matrices for local drug delivery, including postsurgical pain and surgical site infections. Its local sustained-release approach directly parallels Sustained Therapeutics' ST-01 concept.
  • Aclaris Therapeutics: Aclaris is a clinical-stage specialty pharma developing novel therapeutics in immunology and oncology. Comparable as a small-cap clinical-stage pharma pursuing reformulation and novel delivery approaches in specialty indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sustained Therapeutics social profiles

Digital presence

Sustained Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sustained Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Sustained Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sustained Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sustained Therapeutics

What does Sustained Therapeutics do?

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a proprietary soft polymer gel drug delivery platform that enables sustained-release, localized injectable therapeutics. The company is advancing a pipeline of candidates targeting non-opioid pain management, urologic oncology, and sexual dysfunction, with three lead programs (ST-01, ST-02, ST-04) currently in or nearing Phase II clinical trials. Products are designed to deliver drug payloads over days, weeks, or months from a single injection at the targeted body site.

Is Sustained Therapeutics a public or private company?

Sustained Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sustained Therapeutics founded?

Sustained Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Sustained Therapeutics based?

Sustained Therapeutics is headquartered in Vancouver, Canada, in the North America region.

How does Sustained Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Sustained Therapeutics's main competitors?

Veru Inc. is listed as a regional player. Direct peers are Heron Therapeutics, DURECT Corporation and Pacira BioSciences. Broad incumbents are Endo Pharmaceuticals and Collegium Pharmaceutical. Emerging players are Aquestive Therapeutics, Trevena Inc., Innocoll Pharmaceuticals and Aclaris Therapeutics.

Does Sustained Therapeutics have an API?

No public API is recorded for Sustained Therapeutics.

What industry is Sustained Therapeutics in?

Sustained Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarCelebrating Excellence: Life Sciences BC Announces 2026 Award WinnersLife Sciences BC announced the 2026 award winners, including Kardium as Company of the Year and NervGen as Emerging Company of the Year. The winners will be honored at the gala on September 9, 2026, at the Vancouver Convention Centre West.Business Wire BlogSustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual MeetingSustained Therapeutics presented positive Phase 2 data for its non-opioid drug ST-01 at the American Urological Association 2026 Annual Meeting in Washington, DC, showing statistically significant pain reduction in men with chronic scrotal content pain. At the 70 mg/mL dose, 67% of patients achieved treatment response versus 26% in the control arm (p=0.01), and 83% achieved clinical response versus 32% in control (p=0.001). The company plans to advance ST-01 toward Phase 3 development pending regulatory review, targeting a condition affecting an estimated 5 million men in North America.PR NewswireSustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic PainSustained Therapeutics Inc. announced positive Phase 2 clinical trial results for ST-01, its long-acting non-opioid medication for chronic scrotal pain, with the study meeting both primary and secondary endpoints across 63 patients at eight Canadian clinical sites. The company plans to seek regulatory approval to advance into Phase 3 trials in Canada and the United States, while also exploring the drug's potential for other chronic pain indications including chronic pelvic pain and trigeminal neuralgia. The results support the company's broader mission to address the opioid epidemic by providing sustained, localized pain relief without dependency risks.PR NewswireSustained Therapeutics Announces Second Phase II Trial of New Drug PlatformSustained Therapeutics, a Vancouver-based clinical-stage company, has begun a second Phase II trial of its novel non-opioid pain medication ST-01, focusing on treating Chronic Scrotal Pain (CSP). The trial received regulatory clearance from Health Canada in December 2022 and has enrolled its first patient across four sites in Canada, with recruitment expected to take approximately one year followed by six months of follow-up. The company is addressing a high unmet medical need, as an estimated 1 to 6 million men in the US suffer from CSP with limited effective treatment options currently available.PR NewswireSustained Therapeutics Advancing Clinical Trials for Novel Drug Delivery PlatformSustained Therapeutics, a Vancouver-based clinical-stage company, has received a No Objection Letter from Health Canada to begin a second Phase II clinical trial for its novel sustained-release non-opioid pain medication. The five-center study will evaluate treatment for chronic pain, with patient enrollment expected in Q1 2023, following successful Phase I results showing 75% of participants experienced reduced pain scores lasting up to four weeks from a single dose. The company also has another Phase II trial underway for acute pain using the same technology platform.SecSEC FORM DSustained Therapeutics Inc., a Canadian biotechnology company, filed a Form D with the U.S. Securities and Exchange Commission to report an exempt securities offering under Rule 506(b). The filing indicates a minimum investment threshold of $100,000 USD for accredited investors, with proceeds intended for general corporate purposes including executive salaries.